Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Greenwich Lifesciences Inc (GLSI)

Greenwich Lifesciences Inc (GLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,500
  • Shares Outstanding, K 13,145
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,890 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 32.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.21
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.73 +1.19%
on 12/26/24
15.47 -23.27%
on 12/02/24
-2.48 (-17.28%)
since 11/26/24
3-Month
11.73 +1.19%
on 12/26/24
15.47 -23.27%
on 12/02/24
-2.45 (-17.11%)
since 09/26/24
52-Week
8.00 +48.38%
on 02/05/24
21.44 -44.64%
on 03/27/24
+0.75 (+6.74%)
since 12/26/23

Most Recent Stories

More News
Greenwich LifeSciences, Inc. Partners with Italian Clinical Sites for Phase III FLAMINGO-01 Trial on GLSI-100 for Breast Cancer Recurrence Prevention

Greenwich LifeSciences partners with Italian clinical sites for its Phase III FLAMINGO-01 trial evaluating GLSI-100 for breast cancer prevention.Quiver AI SummaryGreenwich LifeSciences, Inc. has announced...

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences Partners with GIM in Italy

GLSI : 11.87 (-2.78%)
Insider Purchase: VP Clinical Reg Affairs of $GLSI (GLSI) Buys 1,000 Shares

Jaye Thompson, the VP Clinical Reg Affairs of $GLSI ($GLSI), bought 1,000 shares of the company on 11-21-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences, Inc. Announces Updates on 2024 Corporate Events and FLAMINGO-01 Clinical Trial Progress

Greenwich LifeSciences updates corporate events and details ongoing Phase III trial of GLSI-100 for breast cancer.Quiver AI SummaryGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company,...

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences Provides Update on Corporate Events

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 11.87 (-2.78%)
Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...

GLSI : 11.87 (-2.78%)

Business Summary

Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company's product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford,...

See More

Key Turning Points

3rd Resistance Point 13.02
2nd Resistance Point 12.74
1st Resistance Point 12.30
Last Price 11.87
1st Support Level 11.58
2nd Support Level 11.30
3rd Support Level 10.86

See More

52-Week High 21.44
Fibonacci 61.8% 16.31
Fibonacci 50% 14.72
Fibonacci 38.2% 13.13
Last Price 11.87
52-Week Low 8.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar